Download ppt - Geriatric Pharmacotherapy

Transcript
Page 1: Geriatric Pharmacotherapy

Geriatric Geriatric PharmacotherapyPharmacotherapy

Page 2: Geriatric Pharmacotherapy

ObjectivesObjectives

1.1. Understand key issues in geriatric Understand key issues in geriatric pharmacotherapypharmacotherapy

2.2. Understand the effect age on Understand the effect age on pharmacokinetics and pharmacokinetics and pharmacodynamicspharmacodynamics

3.3. Discuss risk factors for adverse drug Discuss risk factors for adverse drug events and ways to diminish themevents and ways to diminish them

4.4. Understand the principles of drug Understand the principles of drug prescribing for older patientsprescribing for older patients

Page 3: Geriatric Pharmacotherapy

The Aging ImperativeThe Aging Imperative

Persons aged 65y and Persons aged 65y and older constitute 13% older constitute 13% of the population and of the population and purchase 33% of all purchase 33% of all prescription prescription medicationsmedications

By 2040, 25% of the By 2040, 25% of the population will population will purchase 50% of all purchase 50% of all prescription drugsprescription drugs

Page 4: Geriatric Pharmacotherapy

Challenges of Geriatric Challenges of Geriatric PharmacotherapyPharmacotherapy

New drugs available each yearNew drugs available each year FDA approved and off-label indications are FDA approved and off-label indications are

expandingexpanding Advanced understanding of drug-drug Advanced understanding of drug-drug

interactionsinteractions Increasing popularity of “nutriceuticals”Increasing popularity of “nutriceuticals” PolypharmacyPolypharmacy Medication complianceMedication compliance Effects of aging physiology on drug therapyEffects of aging physiology on drug therapy Medication costMedication cost

Page 5: Geriatric Pharmacotherapy

Pharmacokinetics (PK)Pharmacokinetics (PK) AbsorptionAbsorption

– bioavailabilitybioavailability: the fraction of a drug dose reaching the : the fraction of a drug dose reaching the systemic circulationsystemic circulation

DistributionDistribution– locations in the body a drug penetrates expressed as locations in the body a drug penetrates expressed as

volume per weight (e.g. L/kg)volume per weight (e.g. L/kg)

MetabolismMetabolism– drug conversion to alternate compounds which may be drug conversion to alternate compounds which may be

pharmacologically active or inactivepharmacologically active or inactive

EliminationElimination– a drug’s final route(s) of exit from the body expressed in a drug’s final route(s) of exit from the body expressed in

terms of half-life or clearanceterms of half-life or clearance

Page 6: Geriatric Pharmacotherapy

Age-related changes which Age-related changes which affect pharmacokineticsaffect pharmacokinetics• decreased lean body massdecreased lean body mass

affects drug distributionaffects drug distribution

• decreased levels of serum albumindecreased levels of serum albumin affects drug distributionaffects drug distribution

• decreased liver functiondecreased liver function affects drug metabolism/biotransformationaffects drug metabolism/biotransformation

• decreased renal functiondecreased renal functionaffects drug eliminationaffects drug elimination

Page 7: Geriatric Pharmacotherapy

Effects of Aging on Effects of Aging on AbsorptionAbsorption

Rate of absorption may Rate of absorption may be delayedbe delayed– Lower peak concentrationLower peak concentration– Delayed time to peak Delayed time to peak

concentrationconcentration Overall amount Overall amount

absorbed absorbed (bioavailability) is (bioavailability) is unchangedunchanged

Page 8: Geriatric Pharmacotherapy

Hepatic First-Pass Hepatic First-Pass MetabolismMetabolism

For drugs with extensive first-pass For drugs with extensive first-pass metabolism, bioavailability may metabolism, bioavailability may increase because less drug is increase because less drug is extracted by the liverextracted by the liver– Decreased liver massDecreased liver mass– Decreased liver blood flowDecreased liver blood flow

Page 9: Geriatric Pharmacotherapy

Factors Affecting AbsorptionFactors Affecting Absorption

Route of administrationRoute of administration What it taken with the drugWhat it taken with the drug

– Divalent cations (Ca, Mg, Fe)Divalent cations (Ca, Mg, Fe)– Food, enteral feedingsFood, enteral feedings– Drugs that influence gastric pHDrugs that influence gastric pH– Drugs that promote or delay GI motilityDrugs that promote or delay GI motility

Increased GI pHIncreased GI pH Decreased gastric emptyingDecreased gastric emptying DysphagiaDysphagia

Page 10: Geriatric Pharmacotherapy

Effects of Aging on Volume of Effects of Aging on Volume of Distribution (Vd)Distribution (Vd)

Aging EffectAging Effect Vd EffectVd Effect ExamplesExamples body waterbody water Vd for Vd for

hydrophilic drugshydrophilic drugsethanol, lithiumethanol, lithium

lean body masslean body mass Vd for for drugs Vd for for drugs that bind to that bind to musclemuscle

digoxindigoxin

fat storesfat stores Vd for lipophilic Vd for lipophilic drugsdrugs

diazepam, trazodonediazepam, trazodone

plasma protein plasma protein (albumin)(albumin)

% of unbound % of unbound or free drug or free drug (active)(active)

diazepam, valproic diazepam, valproic acid, phenytoin, acid, phenytoin, warfarinwarfarin

plasma protein plasma protein

((11-acid -acid glycoprotein)glycoprotein)

% of unbound % of unbound or free drug or free drug (active)(active)

quinidine, propranolol, quinidine, propranolol, erythromycin, erythromycin, amitriptylineamitriptyline

Page 11: Geriatric Pharmacotherapy

Aging Effects on Hepatic Aging Effects on Hepatic MetabolismMetabolism

Metabolic clearance of drugs by the Metabolic clearance of drugs by the liver may be reduced due to:liver may be reduced due to:– decreased hepatic blood flowdecreased hepatic blood flow– decreased liver size and massdecreased liver size and mass

ExamplesExamples: morphine, meperidine, : morphine, meperidine, metoprolol, propranolol, verapamil, metoprolol, propranolol, verapamil, amitryptyline, nortriptylineamitryptyline, nortriptyline

Page 12: Geriatric Pharmacotherapy

Metabolic PathwaysMetabolic Pathways

PathwayPathway EffectEffect ExamplesExamples

Phase IPhase I: oxidation, : oxidation, hydroxylation, hydroxylation, dealkylation, dealkylation, reductionreduction

Conversion to Conversion to metabolites of metabolites of lesser, equal, or lesser, equal, or greatergreater

diazepam, diazepam, quinidine, quinidine, piroxicam, piroxicam, theophyllinetheophylline

Phase IIPhase II: : glucuronidation, glucuronidation, conjugation, or conjugation, or acetylationacetylation

Conversion to Conversion to inactive inactive metabolitesmetabolites

lorazepam, lorazepam, oxazepam, oxazepam, temazepamtemazepam

** NOTE: Medications undergoing Phase II hepatic metabolism are generally preferred in the elderly due to inactive metabolites (no accumulation)

Page 13: Geriatric Pharmacotherapy

enzymatic reactions preparing drugs for enzymatic reactions preparing drugs for elimination elimination

Phase I reactions:Phase I reactions:• oxidation: catalyzed by cytochrome Poxidation: catalyzed by cytochrome P450450 enzymes enzymes

Phase II reactions:Phase II reactions:• conjugation: addition of small chemical groups conjugation: addition of small chemical groups

which increase solubility to facilitate eliminationwhich increase solubility to facilitate elimination

•decrease in hepatic blood flow often associated with decreased First Pass Effect•Phase I metabolism decreased•Phase II metabolism generally preserved

Page 14: Geriatric Pharmacotherapy

Other Factors Affecting Drug Other Factors Affecting Drug MetabolismMetabolism

GenderGender SmokingSmoking DietDiet Drug interactionsDrug interactions RaceRace WeaknessWeakness

Page 15: Geriatric Pharmacotherapy

Concepts in Drug Concepts in Drug EliminationElimination

Half-lifeHalf-life– time for serum concentration of drug to time for serum concentration of drug to

decline by 50% (expressed in hours)decline by 50% (expressed in hours) ClearanceClearance

– volume of serum from which the drug is volume of serum from which the drug is removed per unit of time (mL/min or removed per unit of time (mL/min or L/hr)L/hr)

Page 16: Geriatric Pharmacotherapy

Drug elimination Drug elimination changes in the elderlychanges in the elderly

decrease in renal decrease in renal functionsfunctions• decreased blood flow decreased blood flow

to the kidneysto the kidneys• decreased glomerular decreased glomerular

filtrationfiltration• decreased tubular decreased tubular

secretionsecretion• decline in creatinine decline in creatinine

clearanceclearanceReduced elimination drug accumulation and toxicity

Page 17: Geriatric Pharmacotherapy

Effects of Aging on the Effects of Aging on the KidneyKidney

Decreased kidney sizeDecreased kidney size Decreased renal blood flowDecreased renal blood flow Decreased number of functional Decreased number of functional

nephronsnephrons Decreased tubular secretionDecreased tubular secretion Result: Result: glomerular filtration rate (GFR) glomerular filtration rate (GFR) Decreased drug clearanceDecreased drug clearance: atenolol, : atenolol,

gabapentin, H2 blockers, digoxin, gabapentin, H2 blockers, digoxin, allopurinol, quinolonesallopurinol, quinolones

Page 18: Geriatric Pharmacotherapy

Estimating GFR in the Estimating GFR in the ElderlyElderly

Creatinine clearance (CrCl) is used to Creatinine clearance (CrCl) is used to estimate glomerular rateestimate glomerular rate

Serum creatinine alone not accurate in the Serum creatinine alone not accurate in the elderlyelderly lean body mass lean body mass lower creatinine lower creatinine

productionproduction glomerular filtration rateglomerular filtration rate

Serum creatinine stays in normal range, Serum creatinine stays in normal range, masking change in creatinine clearancemasking change in creatinine clearance

Page 19: Geriatric Pharmacotherapy

Example: Creatinine Example: Creatinine Clearance vs. Age in a 5’5”, Clearance vs. Age in a 5’5”,

55 kg Woman55 kg Woman

30301.11.19090

41411.11.17070

53531.11.15050

65651.11.13030

CrClCrClScrScrAgeAge

Page 20: Geriatric Pharmacotherapy

Pharmacodynamics (PD)Pharmacodynamics (PD)

Definition: the time course and intensity of Definition: the time course and intensity of pharmacologic effect of a drugpharmacologic effect of a drug

Age-related changes:Age-related changes: sensitivity to sedation and psychomotor sensitivity to sedation and psychomotor

impairment with impairment with benzodiazepinesbenzodiazepines level and duration of pain relief with level and duration of pain relief with narcotic narcotic

agentsagents drowsiness and lateral sway with drowsiness and lateral sway with alcoholalcohol HR response to HR response to beta-blockersbeta-blockers sensitivity to sensitivity to anti-cholinergic agentsanti-cholinergic agents cardiac sensitivity to cardiac sensitivity to digoxindigoxin

Page 21: Geriatric Pharmacotherapy

PK and PD SummaryPK and PD Summary

PK and PD changes generally result in PK and PD changes generally result in decreased clearance and increased decreased clearance and increased sensitivity to medications in older adultssensitivity to medications in older adults

Use of lower doses, longer intervals, Use of lower doses, longer intervals, slower titration are helpful in decreasing slower titration are helpful in decreasing the risk of drug intolerance and toxicitythe risk of drug intolerance and toxicity

Careful monitoring is necessary to Careful monitoring is necessary to ensure successful outcomesensure successful outcomes

Page 22: Geriatric Pharmacotherapy

Optimal PharmacotherapyOptimal Pharmacotherapy

Balance between overprescribing and Balance between overprescribing and underprescribingunderprescribing– Correct drugCorrect drug– Correct doseCorrect dose– Targets appropriate conditionTargets appropriate condition– Is appropriate for the patientIs appropriate for the patient

Avoid “a pill for every ill”Avoid “a pill for every ill”Always consider non-pharmacologic Always consider non-pharmacologic

therapytherapy

Page 23: Geriatric Pharmacotherapy

Consequences of Consequences of OverprescribingOverprescribing

Adverse drug events (ADEs)Adverse drug events (ADEs) Drug interactionsDrug interactions Duplication of drug therapyDuplication of drug therapy Decreased quality of lifeDecreased quality of life Unnecessary costUnnecessary cost

Page 24: Geriatric Pharmacotherapy

Adverse Drug Events (ADEs)Adverse Drug Events (ADEs) Responsible for 5-28% of Responsible for 5-28% of

acute geriatric hospital acute geriatric hospital admissionsadmissions

Greater than 95% of ADEs Greater than 95% of ADEs in the elderly are in the elderly are considered predictable considered predictable and approximately 50% and approximately 50% are considered are considered preventablepreventable

Most errors occur at the Most errors occur at the ordering and monitoring ordering and monitoring stagesstages

Page 25: Geriatric Pharmacotherapy

Most Common Medications Most Common Medications Associated with ADEs in the Associated with ADEs in the

ElderlyElderly

Opioid analgesicsOpioid analgesics NSAIDsNSAIDs AnticholinergicsAnticholinergics BenzodiazepinesBenzodiazepines AlsoAlso: cardiovascular agents, CNS : cardiovascular agents, CNS

agents, and musculoskeletal agentsagents, and musculoskeletal agents

Adverse Drug Reaction Risk Factors in Older Outpatients. Am J Ger Pharmacotherapy 2003;1(2):82-89.Adverse Drug Reaction Risk Factors in Older Outpatients. Am J Ger Pharmacotherapy 2003;1(2):82-89.

Page 26: Geriatric Pharmacotherapy

The CriteriaThe Criteria

High Potential for High Potential for

Severe ADESevere ADEHigh Potential for High Potential for

Less Severe ADELess Severe ADE

amitriptylineamitriptyline

chlorpropamidechlorpropamide

digoxin >0.125mg/ddigoxin >0.125mg/d

disopyramidedisopyramide

GI antispasmodicsGI antispasmodics

meperidinemeperidine

methyldopamethyldopa

pentazocinepentazocine

ticlopidineticlopidine

antihistamines antihistamines

diphenhydraminediphenhydramine

dipyridamoledipyridamole

ergot mesyloidsergot mesyloids

indomethacinindomethacin

muscle relaxantsmuscle relaxants

Page 27: Geriatric Pharmacotherapy

Patient Risk Factors for Patient Risk Factors for ADEsADEs

PolypharmacyPolypharmacy Multiple co-morbid conditionsMultiple co-morbid conditions Prior adverse drug eventPrior adverse drug event Low body weight or body mass indexLow body weight or body mass index Age > 85 yearsAge > 85 years Estimated CrCl <50 mL/minEstimated CrCl <50 mL/min

Page 28: Geriatric Pharmacotherapy

Drug-Drug Interactions Drug-Drug Interactions (DDIs)(DDIs)

May lead to adverse drug eventsMay lead to adverse drug events Likelihood Likelihood as number of medications as number of medications Most common DDIs:Most common DDIs:

– cardiovascular drugscardiovascular drugs– psychotropic drugspsychotropic drugs

Most common drug interaction effects:Most common drug interaction effects:– confusion confusion – cognitive impairmentcognitive impairment– hypotensionhypotension– acute renal failureacute renal failure

Page 29: Geriatric Pharmacotherapy

Concepts in Drug-Drug Concepts in Drug-Drug InteractionsInteractions

Absorption may be Absorption may be or or Drugs with similar effects can result Drugs with similar effects can result

additive effectsadditive effects Drugs with opposite effects can Drugs with opposite effects can

antagonize each otherantagonize each other Drug metabolism may be inhibited or Drug metabolism may be inhibited or

inducedinduced

Page 30: Geriatric Pharmacotherapy

Common Drug-Drug Common Drug-Drug InteractionsInteractions

CombinationCombination RiskRiskACE inhibitor + potassiumACE inhibitor + potassium HyperkalemiaHyperkalemia

ACE inhibitor + K sparing diureticACE inhibitor + K sparing diuretic Hyperkalemia, hypotensionHyperkalemia, hypotension

Digoxin + antiarrhythmicDigoxin + antiarrhythmic Bradycardia, arrhythmiaBradycardia, arrhythmia

Digoxin + diureticDigoxin + diuretic

Antiarrhythmic + diureticAntiarrhythmic + diureticElectrolyte imbalance; arrhythmiaElectrolyte imbalance; arrhythmia

Diuretic + diureticDiuretic + diuretic Electrolyte imbalance; Electrolyte imbalance; dehydrationdehydration

Benzodiazepine + antidepressantBenzodiazepine + antidepressant

Benzodiazepine + antipsychoticBenzodiazepine + antipsychoticSedation; confusion; fallsSedation; confusion; falls

Nitrate/vasodilator/diureticNitrate/vasodilator/diuretic Hypotension Hypotension

Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996;44(9):944-948.

Page 31: Geriatric Pharmacotherapy

Drug-Disease InteractionsDrug-Disease Interactions

Obesity alters Vd of lipophilic drugsObesity alters Vd of lipophilic drugs Ascites alters Vd of hydrophilic drugsAscites alters Vd of hydrophilic drugs Dementia may Dementia may sensitivity, induce sensitivity, induce

paradoxical reactions to drugs with CNS paradoxical reactions to drugs with CNS or anticholinergic activityor anticholinergic activity

Renal or hepatic impairment may Renal or hepatic impairment may impair metabolism and excretions of impair metabolism and excretions of drugsdrugs

Drugs may worsen a medical conditionDrugs may worsen a medical condition

Page 32: Geriatric Pharmacotherapy

Common Drug-Disease Common Drug-Disease InteractionsInteractions

CombinationCombination RiskRisk

NSAIDs + CHFNSAIDs + CHF

Thiazolidinediones + CHFThiazolidinediones + CHFFluid retention; CHF exacerbationFluid retention; CHF exacerbation

BPH + anticholinergicsBPH + anticholinergics Urinary retentionUrinary retention

Narcotics + constipationNarcotics + constipation

Anticholinergics + constipationAnticholinergics + constipationExacerbation of constipationExacerbation of constipation

Metformin + CHFMetformin + CHF Hypoxia; increased risk of lactic Hypoxia; increased risk of lactic acidosisacidosis

NSAIDs + gastropathyNSAIDs + gastropathy Increased ulcer and bleeding riskIncreased ulcer and bleeding risk

NSAIDs + HTNNSAIDs + HTN Fluid retention; decreased Fluid retention; decreased effectiveness of diureticseffectiveness of diuretics

Page 33: Geriatric Pharmacotherapy

Principles of Prescribing in the Principles of Prescribing in the ElderlyElderly

Avoid prescribing prior to diagnosisAvoid prescribing prior to diagnosis Start with a low dose and titrate Start with a low dose and titrate

slowlyslowly Avoid starting 2 agents at the same Avoid starting 2 agents at the same

timetime Reach therapeutic dose before Reach therapeutic dose before

switching or adding agentsswitching or adding agents Consider non-pharmacologic agentsConsider non-pharmacologic agents

Page 34: Geriatric Pharmacotherapy

Prescribing AppropriatelyPrescribing Appropriately Determine therapeutic endpoints and plan for Determine therapeutic endpoints and plan for

assessmentassessment Consider risk vs. benefitConsider risk vs. benefit Avoid prescribing to treat side effect of another Avoid prescribing to treat side effect of another

drugdrug Use 1 medication to treat 2 conditionsUse 1 medication to treat 2 conditions Consider drug-drug and drug-disease interactionsConsider drug-drug and drug-disease interactions Use simplest regimen possibleUse simplest regimen possible Adjust doses for renal and hepatic impairmentAdjust doses for renal and hepatic impairment Avoid therapeutic duplicationAvoid therapeutic duplication Use least expensive alternativeUse least expensive alternative

Page 35: Geriatric Pharmacotherapy

Preventing PolypharmacyPreventing Polypharmacy

Review medications regularly and Review medications regularly and each time a new medication started each time a new medication started or dose is changedor dose is changed

Maintain accurate medication Maintain accurate medication records (include vitamins, OTCs, and records (include vitamins, OTCs, and herbals)herbals)

““Brown-bag”Brown-bag”

Page 36: Geriatric Pharmacotherapy

Non-AdherenceNon-Adherence

Rate may be as high as 50% in the Rate may be as high as 50% in the elderlyelderly

Factors in non-adherenceFactors in non-adherence– Financial, cognitive, or functional statusFinancial, cognitive, or functional status– Beliefs and understanding about disease Beliefs and understanding about disease

and medicationsand medications

Page 37: Geriatric Pharmacotherapy

Enhancing Medication Enhancing Medication AdherenceAdherence

Avoid newer, more expensive Avoid newer, more expensive medications that are not shown to be medications that are not shown to be superior to less expensive generic superior to less expensive generic alternativesalternatives

Simplify the regimenSimplify the regimen Utilize pill organizers or drug calendarsUtilize pill organizers or drug calendars Educate patient on medication purpose, Educate patient on medication purpose,

benefits, safety, and potential ADEsbenefits, safety, and potential ADEs

Page 38: Geriatric Pharmacotherapy

SummarySummary

Successful pharmacotherapy means Successful pharmacotherapy means using the correct drug at the correct using the correct drug at the correct dose for the correct indication in an dose for the correct indication in an individual patientindividual patient

Age alters PK and PDAge alters PK and PD ADEs are common among the elderlyADEs are common among the elderly Risk of ADEs can be minimized by Risk of ADEs can be minimized by

appropriate prescribingappropriate prescribing

Page 39: Geriatric Pharmacotherapy

THANK YOU FOR THANK YOU FOR YOUR ATTENTIONYOUR ATTENTION

زندگی چه؟ یعنی

سپهری سهراب

تنگ در ماهی، اندیشه در دریاست باور زندگی،

هاست نفهمیدن فهم زندگی،

ماست رفتن و آمدن خاطره ، زندگی

Page 40: Geriatric Pharmacotherapy

Recommended